While many of the pharma companies are struggling to outsource their accurate forecast models for new and inmarket drugs, MarketsandMarkets on the other hand provides integrated patient-based forecast solutions to various players.
Online PR News – 17-December-2009 – – WILMINGTON, Delaware- While many of the pharma companies are struggling to outsource their accurate forecast models for new and inmarket drugs, MarketsandMarkets on the other hand provides integrated patient-based forecast solutions to various players. These pharma forecasting solutions are designed for phase I, phase II, as well as phase III. These have a substantial impact on pricing, launch, product life cycle management, market entry strategy, manufacturing planning, sales force, promotion, and planning. The leading pharma companies now endorse the forecast solution provided by MarketsandMarkets as the accurate forecast model, comprising of significant cost benefit analysis for an annual contract basis. The forecasts are based on epidemiology and actual patients on drugs. The primary and secondary research analytics underlying the forecast include:
- Epidemiology analysis
- Treated patients best fit trending
- Polypharmacy ratio analysis
- Competitive landscape analysis
- Analogue analysis for uptake, time to peak, and generic erosion
- Conjoint / discrete choice / attribute analysis
- Calibration based on actual sales and impact of various events
The treated patient pool potential is determined by prevalence, incidence, diagnosis, treatment, cure, and mortality rate. The treated patient pool is also back-calculated simultaneously from historic and present product sales. Trending and smoothening takes into account seasonality and the impact of other events on sale. The conjoint / discrete choice analysis uses primary research to estimate peak patient share for new products. In absence of primary research due to budget / time constraints, an attribute analysis is done using secondary research and consumer inputs to estimate peak patient share for new products.
The peak patient share calculation mechanism is calibrated based on shares of existing products. Ratio of treated patient pool, based on patient on products and epi, gives polypharmacy ratio. Analogues are identified based on disease area, TPP, MoA, order of entry, and market dynamics to estimate time to peak, shape of uptake curve, generic erosion, and impact of other events. Share exchange / cannibalization is done based on fair-share approach or inputs from brand team along with secondary and primary research.
Simple and transparent VB- and Excel-based forecast models: models are developed based on forecast complexity and the functional need of end-user. Our team has expertise in designing and developing VB- and Excel-based forecast / market models.
Strong quality checks: - quality checks are built up at each stage to ensure foolproof estimates, including triangulation of epi data from multiple sources, calibration based on polypharmacy and actual historic sale, calibration of peak patient share estimation model or peak patient share based on share. Quality checks embedded in the Excel / VB formula in the forecast model.
We have strong team of analysts with experience in executing advanced forecasting projects for both pipeline and in-market products for the top pharma companies globally.
For more details, click on:
MarketsandMarkets is a research and consulting firm that publishes 120 market research reports per year. Each strategically analyzed report contains 250 pages of valuable market data, including more than 100 market data summary tables and in-depth, five-level segmentation for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports also analyze about 200 patents, over 50 companies and micro markets that are mutually exclusive and collectively exhaustive. Browse all our 120 titles at http://www.marketsandmarkets.com.